**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 89316

**Manuscript Type:** EDITORIAL

**Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time**

Hu Y *et al.* Individualized intensive insulin therapy

Yun Hu, Hong-Jing Chen, Jian-Hua Ma

**Yun Hu, Hong-Jing Chen,** Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu Province, China

**Jian-Hua Ma,** Department of Endocrinology, Nanjing First Hospital, Nanjing 210000, Jiangsu Province, China

**Author contributions:** Hu Y and Chen HJ drafted the initial manuscript; Ma JH conceptualized and revised the manuscript.

**Corresponding author: Jian-Hua Ma, MD, Professor,** Department of Endocrinology, Nanjing First Hospital, No. 32 Gongqingtuan Road, Nanjing 210000, Jiangsu Province, China. majianhua@china.com

**Received:** October 27, 2023

**Revised:** December 3, 2023

**Accepted:** December 25, 2023

**Published online:** January 15, 2024

**Abstract**

Intensive insulin therapy has been extensively used to control blood glucose levels because of its ability to reduce the risk of chronic complications of diabetes. According to current guidelines, intensive glycemic control requires individualized glucose goals rather than as low as possible. During intensive therapy, rapid blood glucose reduction can aggravate microvascular and macrovascular complications, and prolonged overuse of insulin can lead to treatment-induced neuropathy and retinopathy, hypoglycemia, obesity, lipodystrophy, and insulin antibody syndrome. Therefore, we need to develop individualized hypoglycemic plans for patients with diabetes, including the time required for blood glucose normalization and the duration of intensive insulin therapy, which deserves further study.

**Key Words:** Diabetes; Intensive therapy; Insulin; Treatment-induced neuropathy

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Hu Y, Chen HJ, Ma JH. Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time. *World J Diabetes* 2024; 15(1): 11-14

**URL**: https://www.wjgnet.com/1948-9358/full/v15/i1/11.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v15.i1.11

**Core Tip****:** Intensive insulin therapy is popular in the treatment of patients with diabetes. This article highlighted the effects and side effects of intensive insulin therapy. It is a warning against the use of insulin therapy without any limitations, such as the speed of blood glucose lowering and the duration of insulin therapy.

**INTRODUCTION**

Intensive insulin therapy refers to the control of blood glucose levels within the normal range using insulin therapy in patients with poor glycemic control. Intensive insulin therapy has been demonstrated to effectively decrease the risk of chronic complications in both patients with type 1 and type 2 diabetes[1,2]. The Diabetes Control and Complications Trial[3] in 1993 and the United Kingdom Prospective Diabetes Study[4] in 1998 are landmark studies that demonstrated the benefits of intensive insulin therapy in type 1 and type 2 diabetes, respectively. Moreover, intensive insulin therapy has favorable outcomes in the recovery and maintenance of β-cell function and protracted glycemic remission compared to treatment with oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes[5]. Therefore, intensive insulin therapy is administered widely among patients with diabetes due to its benefits. Furthermore, the standards of insulin intensive therapy are constantly updated, and the side effects identifiedare summarized briefly in the present commentary.

**INDIVIDUAL GOALS FOR INTENSIVE THERAPY**

Most current diabetes guidelines recommend individualized goals for intensive glycemic control. The Action to Control Cardiovascular Risk in Diabetes study found that low glycemic control with a goal of HbA1c < 6.0% led to increased mortality in patients with type 2 diabetes[6]. As such, the goal of intensive therapy is not as low as possible, and the increased risk of hypoglycemia should be considered. According to the guidelines of the American Diabetes Association and the Chinese Diabetes Society, the reasonable HbA1c goal for most nonpregnant adults is < 7%, which is beneficial for reducing microvascular and macrovascular complications in type 1 and type 2 diabetes[7,8]. The East African Diabetes Study Group recommended a target HbA1c of 7.5% for all children with type 1 diabetes mellitus[9]. More stringent HbA1c targets (such as < 6.5%, or even close to the normal reference value) and less stringent HbA1c goals (such as < 8.0%) are indicated depending on the duration of disease, life expectancy, complications, risk of hypoglycemia, and other adverse effects of treatment[10,11].

**SIDE EFFECTS OF RAPID BLOOD GLUCOSE REDUCTION**

Clinicians and even patients usually recommend blood glucose recovery to the glycemic target as soon as possible during intensive therapy, usually within a week[5,12], and this is the same when patients initially use an automatic insulin delivery system[13,14]. During intensive therapy, HbA1c can be dramatically reduced by more than 1.5%-2% in 3-4 mo[15,16], and 3%-4% in a year[16,17]. Several studies have reported that rapid blood glucose reduction can aggravate various complications, including cardiovascular events[16], retinopathy[17], nephropathy[18] and neuropathy[15,19]. Neuropathy induced by an abrupt improvement in glycemic control is called treatment-induced neuropathy in diabetes (also referred to as insulin neuritis). All these complications commonly occur in patients with chronic hyperglycemia, the incidence rate and severity are positively correlated with the magnitude and speed of the decrease in HbA1c[15,16]. Therefore, the planning of a individualized intensive therapy program to prevent these complications requires further research. Hence, the duration of hyperglycemia, HbA1c levels, and preexisting complications at baseline should be considered.

**OVERUSE OF INSULIN IN PATIENTS WITH TYPE 2 DIABETES**

With the popularity of short-term intensive therapy, many patients with type 2 diabetes are prescribed insulin therapy at the time of the new diagnosis; However, some of these patients do not evaluate the possibility of insulin withdrawal in time[20]. Some patients had been using insulin for several years. Although these patients can maintain good glycemic control, the excessive and prolonged use of insulin can result in certain side effects. More treatment-induced neuropathy and retinopathy have been reported in patients receiving insulin therapy than in patients treated with oral hypoglycemic agents[21]. Not only because insulin reduces HbA1c the most[22] but because the abnormal activation of the insulin-IGF-1-AKT signaling pathway may exacerbate these complications[22,23]. In our previous study using ﬂash glucose monitoring, about 40% of patients with type 2 diabetes using premixed insulin had time below range ≥ 4%, illustrating a high proportion of hypoglycemia; Meanwhile, the proportion of oral hypoglycemic agents treatments combination was less than 50%[24]. Moreover, the long-term use of insulin and hyperinsulinemia in patients with type 2 diabetes may lead to obesity[25] and insulin resistance, lipodystrophy[26,27], and exogenous insulin antibody syndrome[28]. These problems lead to the deterioration of glycemic control. Therefore, when and under what circumstances intensive insulin therapy can be stopped and switched to oral hypoglycemic agents must be emphasized in patients newly diagnosed with type 2 diabetes.

**CONCLUSION**

To control the side effects of intensive insulin therapy, individualized glycemic goals and hypoglycemic plans need to be developed for patients, including the time required for blood glucose levels to reach the target and the duration of intensive insulin therapy. Oral glucose-lowering drugs and the GLP-1 receptor agonist adjunct to insulin can help reduce the insulin dose and improve glycemic variations[29,30], and should be initiated simultaneously with intensive insulin therapy in patients with type 2 diabetes and even in some patients with type 1 diabetes who have insulin resistance[31]. Furthermore, some nerve and microvascular protectors, such as epalrestat[32], mecobalamin[33], and pancreatic kininogenase[34], may helpprevent these complications of intensive therapy, which needs further clinical studies.

**REFERENCES**

1 **Stratton IM**, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; **321**: 405-412 [PMID: 10938048 DOI: 10.1136/bmj.321.7258.405]

2 **Holman RR**, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; **359**: 1577-1589 [PMID: 18784090 DOI: 10.1056/NEJMoa0806470]

3 **Diabetes Control and Complications Trial Research Group**, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; **329**: 977-986 [PMID: 8366922 DOI: 10.1056/NEJM199309303291401]

4 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853 [PMID: 9742976]

5 **Weng J**, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet* 2008; **371**: 1753-1760 [PMID: 18502299 DOI: 10.1016/S0140-6736(08)60762-X]

6 **Action to Control Cardiovascular Risk in Diabetes Study Group**, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; **358**: 2545-2559 [PMID: 18539917 DOI: 10.1056/NEJMoa0802743]

7 **Laiteerapong N**, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). *Diabetes Care* 2019; **42**: 416-426 [PMID: 30104301 DOI: 10.2337/dc17-1144]

8 **Lind M**, Pivodic A, Svensson AM, Ólafsdóttir AF, Wedel H, Ludvigsson J. HbA(1c) level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. *BMJ* 2019; **366**: l4894 [PMID: 31462492 DOI: 10.1136/bmj.l4894]

9 **Silver B**, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, Charlotte BM, Claudine K, Makhoba A. EADSG Guidelines: Insulin Therapy in Diabetes. *Diabetes Ther* 2018; **9**: 449-492 [PMID: 29508275 DOI: 10.1007/s13300-018-0384-6]

10 **ElSayed NA**, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 6. Glycemic Targets: Standards of Care in Diabetes-2023. *Diabetes Care* 2023; **46**: S97-S110 [PMID: 36507646 DOI: 10.2337/dc23-S006]

11 **Jia W**, Weng J, Zhu D, Ji L, Lu J, Zhou Z, Zou D, Guo L, Ji Q, Chen L, Chen L, Dou J, Guo X, Kuang H, Li L, Li Q, Li X, Liu J, Ran X, Shi L, Song G, Xiao X, Yang L, Zhao Z; Chinese Diabetes Society. Standards of medical care for type 2 diabetes in China 2019. *Diabetes Metab Res Rev* 2019; **35**: e3158 [PMID: 30908791 DOI: 10.1002/dmrr.3158]

12 **Hu Y**, Ding B, Shen Y, Yan RN, Li FF, Sun R, Jing T, Lee KO, Ma JH. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin. *Diabetes Care* 2021; **44**: 1059-1061 [PMID: 33536253 DOI: 10.2337/dc20-1558]

13 **Russell SJ**, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. *N Engl J Med* 2014; **371**: 313-325 [PMID: 24931572 DOI: 10.1056/NEJMoa1314474]

14 **Phillip M**, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. *Endocr Rev* 2023; **44**: 254-280 [PMID: 36066457 DOI: 10.1210/endrev/bnac022]

15 **Gibbons CH**, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. *Brain* 2015; **138**: 43-52 [PMID: 25392197 DOI: 10.1093/brain/awu307]

16 **Rigalleau V**, Larroumet A, Ducos C, Rigo M, Barbet-Massin MA, Majchrzak C, Mohammedi K, Baillet-Blanco L, Monlun M, Rami-Arab L, Foussard N. Cardiovascular events after a dramatic reduction of HbA1c in hospitalized subjects with type 2 diabetes and high long-term glucose exposure. *J Diabetes Complications* 2022; **36**: 108234 [PMID: 35752528 DOI: 10.1016/j.jdiacomp.2022.108234]

17 **Shurter A**, Genter P, Ouyang D, Ipp E. Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. *Diabetes Res Clin Pract* 2013; **100**: 362-367 [PMID: 23566652 DOI: 10.1016/j.diabres.2013.03.018]

18 **Cundy T**, Holden A, Stallworthy E. Early Worsening of Diabetic Nephropathy in Type 2 Diabetes After Rapid Improvement in Chronic Severe Hyperglycemia. *Diabetes Care* 2021; **44**: e55-e56 [PMID: 33483357 DOI: 10.2337/dc20-2646]

19 **Ferreira M**, Camoes G, Gomes JFF, Ferreira DM. Treatment-induced diabetes neuropathy: reminder of an important clinical lesson. *BMJ Case Rep* 2021; **14** [PMID: 34016633 DOI: 10.1136/bcr-2021-241849]

20 **Grant RW**, Buse JB, Meigs JB; University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. *Diabetes Care* 2005; **28**: 337-442 [PMID: 15677789 DOI: 10.2337/diacare.28.2.337]

21 **Nicodemus JM**, Enriquez C, Marquez A, Anaya CJ, Jolivalt CG. Murine model and mechanisms of treatment-induced painful diabetic neuropathy. *Neuroscience* 2017; **354**: 136-145 [PMID: 28476321 DOI: 10.1016/j.neuroscience.2017.04.036]

22 **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; **32**: 193-203 [PMID: 18945920 DOI: 10.2337/dc08-9025]

23 **Chen HS**, Wu TE, Hsiao LC, Lin SH. Interaction between glycaemic control and serum insulin-like growth factor 1 on the risk of retinopathy in type 2 diabetes. *Eur J Clin Invest* 2012; **42**: 447-454 [PMID: 22050075 DOI: 10.1111/j.1365-2362.2011.02616.x]

24 **Yan RN**, Cai TT, Jiang LL, Jing T, Cai L, Xie XJ, Su XF, Xu L, He K, Cheng L, Cheng C, Liu BL, Hu Y, Ma JH. Real-Time Flash Glucose Monitoring Had Better Effects on Daily Glycemic Control Compared With Retrospective Flash Glucose Monitoring in Patients With Type 2 Diabetes on Premix Insulin Therapy. *Front Endocrinol (Lausanne)* 2022; **13**: 832102 [PMID: 35222287 DOI: 10.3389/fendo.2022.832102]

25 **Mathieu C**, Martens PJ, Vangoitsenhoven R. One hundred years of insulin therapy. *Nat Rev Endocrinol* 2021; **17**: 715-725 [PMID: 34404937 DOI: 10.1038/s41574-021-00542-w]

26 **Holstein A**, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. *Expert Opin Drug Saf* 2010; **9**: 225-231 [PMID: 20001763 DOI: 10.1517/14740330903496402]

27 **Radermecker RP**, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. *Am J Clin Dermatol* 2007; **8**: 21-28 [PMID: 17298103 DOI: 10.2165/00128071-200708010-00003]

28 **Huynh T**. Clinical and Laboratory Aspects of Insulin Autoantibody-Mediated Glycaemic Dysregulation and Hyperinsulinaemic Hypoglycaemia: Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome. *Clin Biochem Rev* 2020; **41**: 93-102 [PMID: 33343044 DOI: 10.33176/AACB-20-00008]

29 **Jiang LL**, Zhang P, Liu BL, Yan RN, Ye L, Ma JH, Li FF. Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial. *Biomed Res Int* 2021; **2021**: 6618257 [PMID: 34497852 DOI: 10.1155/2021/6618257]

30 **Li H**, Yang A, Zhao S, Chow EY, Javanbakht M, Li Y, Lin D, Xu L, Zang D, Wang K, Ma L. Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials. *Pharmaceuticals (Basel)* 2022; **15** [PMID: 36015100 DOI: 10.3390/ph15080953]

31 **Zawada A**, Naskręt D, Burchardt P, Niedźwiecki P, Piłaciński S, Wierusz-Wysocka B, Grzymisławski M, Zozulińska-Ziółkiewicz D. Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat. *Pol Arch Intern Med* 2018; **128**: 294-300 [PMID: 29870029 DOI: 10.20452/pamw.4241]

32 **Steele JW**, Faulds D, Goa KL. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. *Drugs Aging* 1993; **3**: 532-555 [PMID: 8312678 DOI: 10.2165/00002512-199303060-00007]

33 **Sawangjit R**, Thongphui S, Chaichompu W, Phumart P. Efficacy and Safety of Mecobalamin on Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Altern Complement Med* 2020; **26**: 1117-1129 [PMID: 32716261 DOI: 10.1089/acm.2020.0068]

34 **Jin YP**, Su XF, Li HQ, Wu JD, Ding B, Sun R, Shan T, Ye L, Ma JH. The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes. *Exp Clin Endocrinol Diabetes* 2016; **124**: 618-621 [PMID: 27701714 DOI: 10.1055/s-0042-107242]

**Footnotes**

**Conflict-of-interest statement:** All the Authors have no conflict of interest related to the manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 27, 2023

**First decision:** November 23, 2023

**Article in press:** December 25, 2023

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Abu Yousuf M, Bangladesh; Balbaa ME, Egypt; Cai L, United States; Horowitz M, Australia **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Xu ZH



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**